Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511362 | 0.95 | PDE4B (0.43) | PDE4BPDE7AEHMT2PIK3CDPIK3R1 | |
| Trifluoroacetic Acid SCHEMBL4526719 | 0.94 | PDE4B (0.41) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| Trifluoroacetic Acid SCHEMBL4517598 | 0.89 | PDE4B (0.48) | PDE4B | |
| SCHEMBL4510509 | 0.88 | PDE4B (0.45) | PDE4BPDE7AEHMT2PIK3CDPIK3R1 | |
| SCHEMBL4528858 | 0.86 | PDE4B (0.42) | PDE4BPDE7AEHMT2PIK3CDPIK3R1 | |
| Trifluoroacetic Acid SCHEMBL4528660 | 0.85 | PDE4B (0.41) | PDE4BPDE4D | |
| SCHEMBL4531325 | 0.84 | PDE4B (0.42) | PDE4BPDE7AEHMT2PIK3CDPIK3R1 | |
| SCHEMBL4519387 | 0.83 | PDE4B (0.44) | PDE4BPDE7AEHMT2PIK3CDPIK3R1 | |
| SCHEMBL4507091 | 0.83 | PDE4B (0.41) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4520179 | 0.83 | PDE4B (0.44) | PDE4BPDE7APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE7A 10/4885EHMT2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.